Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07289763
PHASE2
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
View on ClinicalTrials.gov
Summary
To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
75
Start Date
2025-12-31
Completion Date
2027-09
Last Updated
2026-01-26
Healthy Volunteers
No
Conditions
Interventions
DRUG
SHR-2173 injection
SHR-2173 injection, with a total of 8 administrations
DRUG
SHR-2173 injection
SHR-2173 injection, with a total of 16 administrations
DRUG
SHR-2173 injection
SHR-2173 injection , with a total of 32 administrations
Locations (1)
General hospital of eastern theater command
Nanjing, Jiangsu, China